Clinical Trial Update: Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating the efficacy and safety of DEXTENZA 0.4 mg inserted after corneal transplant surgery; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anterior Chamber Inflammation
• Corneal Defect
• Corneal Edema
• Corneal Transplant
• Intraocular Pressure
• Ocular Pain
• Penetrating Keratoplasty

Drugs mentioned

• Dextenza (Dexamethasone)

Snippet

Sponsor: Nicole Fram M.D. | Conditions: Corneal Edema, Corneal Defect | Phase 4 | Status: COMPLETED